Study of Silodosin to Facilitate Passage of Urinary Stones

Watson Pharmaceuticals239 enrolled

Overview

The purpose of this study is to assess if patients treated with silodosin will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

239

Conditions

Ureteral Calculi Kidney Stones Urolithiasis

Interventions

silodosinDRUG

one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks

placeboDRUG

one placebo capsule orally, once daily, with food for up to 4 weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * At least 18 years of age or older * Male or a non-pregnant, non-lactating female using adequate means of birth control, if not menopausal * Have radiopaque unilateral ureteral calculus ≥4mm and ≤10mm in any location of the ureter Exclusion Criteria: * Multiple ureteral calculi, or a solitary kidney, or refractory renal colic, or a non-opaque calculus, or active urinary tract infection, or severe hydronephrosis * History of previous ureteral surgery or ureteral stricture on affected side * History of any of the following conditions: myasthenia gravis, myopathy, spina bifida, spinal cord injury, autonomic nervous system disorder, fibromyalgia, breast cancer * Moderate to severe renal impairment or severe liver insufficiency * History of significant postural hypotension * Is receiving medication(s) which preclude safe participation in the study or that may produce a confounding effect on the variables under study * History of allergy to alpha-blockers or oxycodone

Locations (27)

Outcomes

Primary Outcomes

Spontaneous Stone Passage (Distal Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.

The primary efficacy variable is the occurrence of spontaneous distal stone passage within 4 weeks, as determined by radiography. For this outcome measure, analysis includes only those stones located in the distal ureter.

Time frame: 4 weeks

Spontaneous Stone Passage (All Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.

The primary efficacy variable is the occurrence of spontaneous stone passage within 4 weeks, as determined by radiography. For this outcome measure, analysis includes all ureteral stones, regardless of location in the ureter.

Time frame: 4 weeks

Secondary Outcomes

Time to Spontaneous Stone Passage (Distal Stones)

Time to stone passage for distally-located stones is assessed by entries in subject diaries.

Time frame: 4 weeks

Outpatient Narcotic Analgesic Use for Pain Relief

Narcotic analgesic use was assessed through a subject diary. Analysis was performed on the number of days with analgesic use.

Time frame: 4 weeks

Change From Baseline in Average Score on the Brief Pain Inventory (Distal Stones)

At each study visit, subjects were given a Brief Pain Inventory (BPI) Questionnaire to complete. The BPI collects subject-reported pain severity scores and assesses impact of pain upon the subject's daily life, on a 10-point scale (with 10 being the greatest severity/impact). Analysis was change from baseline to week 4.

Time frame: 4 weeks

Time to Spontaneous Stone Passage (All Stones)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.